Tocilizumab: a novel therapy for patients with large-vessel vasculitis
Open Access
- 9 November 2011
- journal article
- case report
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 51 (1) , 151-156
Abstract
Objective. Treatment of large-vessel vasculitis (LVV) remains challenging. Patients usually respond to glucocorticoid (GC) therapy, but often relapse on tapering of the GC dose or after GC withdrawal. In addition, GCs are fraught with numerous adverse events. The aim of this study was to assess the efficacy and safety of the anti-IL-6 receptor (IL-6R) antibody tocilizumab (TCZ) in patients with LVV. Methods. Four patients with active LVV (two with GCA and two with Takayasu arteritis) received monthly TCZ infusions (8 mg/kg bodyweight) for 6 consecutive months. Two patients were treatment naïve, while two had relapsing disease. Disease activity and drug tolerability were assessed clinically and by laboratory tests at study entry and subsequently every month for 6 months of TCZ treatment, while an [18F]fluorodeoxyglucose PET (PET/CT) scan was performed before and after treatment. In addition, a semi-quantitative clinical evaluation was performed at baseline and at 3 and 6 months using the Indian Takayasu activity score and the Kerr indices. After TCZ, MTX was used as maintenance therapy. Results. All patients treated with TCZ therapy had a satisfactory clinical and laboratory response, while PET/CT findings significantly improved in all cases. No serious adverse events were noted. Only one patient had a transient increase in liver enzymes. Conclusions. In this small group of patients with LVV, treatment with TCZ was effective and well tolerated. Further, larger studies are required to confirm our findings.Keywords
This publication has 13 references indexed in Scilit:
- A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effectsAnnals of the Rheumatic Diseases, 2008
- Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell ArteritisAnnals of Internal Medicine, 2007
- The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- Anti–tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritisArthritis & Rheumatism, 2004
- Medium- and Large-Vessel VasculitisNew England Journal of Medicine, 2003
- Treatment of glucocorticoid‐resistant or relapsing takayasu arteritis with methotrexateArthritis & Rheumatism, 1994
- Takayasu ArteritisAnnals of Internal Medicine, 1994
- The American College of Rheumatology 1990 criteria for the classification of takayasu arteritisArthritis & Rheumatism, 1990
- The American College of Rheumatology 1990 criteria for the classification of giant cell arteritisArthritis & Rheumatism, 1990
- Pneumonia in an intensive care unit. A 30-month experienceArchives of internal medicine (1960), 1974